12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Regorafenib: Additional Phase III data

Additional data from the double-blind, international Phase III GRID trial in 199 patients showed that oral regorafenib plus best supportive care (BSC) led to median PFS, the primary endpoint, of 4.8 months vs. 0.9 months for placebo plus BSC (HR=0.27, p<0.0001). The most common adverse events were hand-foot skin reactions, hypertension, diarrhea, fatigue, oral mucositis, alopecia, hoarseness, anorexia, myalgia, maculopapular rash, nausea, constipation and voice alteration. The trial enrolled patients with metastatic and/or unresectable GIST whose disease had progressed...

Read the full 375 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >